Last reviewed · How we verify

QuantumLeap Healthcare Collaborative — Portfolio Competitive Intelligence Brief

QuantumLeap Healthcare Collaborative pipeline: 1 marketed, 0 filed, 0 Phase 3, 13 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 13 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Pertuzumab and Trastuzumab Pertuzumab and Trastuzumab marketed HER2-targeted monoclonal antibody combination HER2 (human epidermal growth factor receptor 2) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. European Organisation for Research and Treatment of Cancer - EORTC · 2 shared drug classes
  2. Hoffmann-La Roche · 2 shared drug classes
  3. Bristol-Myers Squibb · 2 shared drug classes
  4. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
  5. HK inno.N Corporation · 2 shared drug classes
  6. Amgen · 2 shared drug classes
  7. Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
  8. Hospices Civils de Lyon · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for QuantumLeap Healthcare Collaborative:

Cite this brief

Drug Landscape (2026). QuantumLeap Healthcare Collaborative — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/quantumleap-healthcare-collaborative. Accessed 2026-05-16.

Related